QLGN (Qualigen Therapeutics) חוב לטווח קצר להון

The Qualigen Therapeutics (QLGN) price chart illustrates a trend currently priced at 0.08. Company management is betting on the creation of advanced diagnostic systems and the search for partners to bring products to market. The development of oncology and antiviral drugs relies on alliances with scientists, which increases the likelihood of an acquisition. Meanwhile, streamlined component supply chains ensure the continuity of all processes.

To identify fundamentally resilient assets, investors assess liquidity via the ratio of liabilities maturing within one year relative to equity, which determines the business's degree of dependence on external financing; in the case of Qualigen Therapeutics (QLGN), this short-term debt-to-equity ratio is critical for evaluating the company's ability to sustain the expansion of its ALAN oncology pipeline without the risk of a sudden cash shortage.